Immune
Thymosin alpha 1 is associated with improved cellular immunity and reduced infection rate in severe acute pancreatitis patients in a double-blind randomized control study
Wang X, Li W, Niu C, Pan L, Li N, Li J. · Inflammation · 2011
PMID: 20549321 · DOI: 10.1007/s10753-010-9217-0
Summary
Double-blind randomized controlled trial of subcutaneous thymosin alpha 1 in adults with severe acute pancreatitis. Endpoints: T-lymphocyte subsets, infection incidence, length of stay.
Citation hosted by NCBI. We link to the source so the researcher can read the abstract, full text, or references-cited list directly.
Compounds referenced in this study
- View product →Thymosin Alpha-1 5mg28-residue acetylated thymic peptide studied in immune-modulation research.
Guides covering this compound
More Immune citations
- The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trialCrit Care · 2013
- The efficacy and safety of thymosin alpha-1 for sepsis (TESTS): multicentre, double blinded, randomised, placebo controlled, phase 3 trialBMJ · 2025
- Efficacy of thymosin alpha1 in patients with chronic hepatitis B: a randomized, controlled trialLiver · 1996